Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joon Ho Moon

Showing results (241-250 of 280) with videos related to

Pageof 28
Sort By:
Annals of Hematology|October 12, 2012
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangementHee-Jin Kim, Hee Kyung Ahn, Chul Won Jung, et al.
Transfusion|March 13, 2015
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overloadIl-Hwan Kim, Joon-Ho Moon, Sung-Nam Lim, et al.
Annals of Hematology|November 6, 2015
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplantJae-Sook Ahn, Jae-Young Kim, Hyeoung-Joon Kim, et al.
Leukemia|December 18, 2018
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemiaJong-Ho Park, Young Min Woo, Emilia Moonkyung Youm, et al.
Blood|August 16, 2018
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapseTaeHyung Kim, Joon Ho Moon, Jae-Sook Ahn, et al.
American Journal of Hematology|August 24, 2017
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapyHyungwoo Cho, Dok Hyun Yoon, Jung Bok Lee, et al.
Bone Marrow Transplantation|September 23, 2022
Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemiaGa-Young Song, TaeHyung Kim, Seo-Yeon Ahn, et al.
Acta Haematologica|December 7, 2011
Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemiaSoo Jung Lee, Byung Woog Kang, Joon Ho Moon, et al.
Annals of Hematology|September 13, 2013
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patientsKihyun Kim, Seok Jin Kim, Verena Voelter, et al.
Blood Research|August 13, 2025
A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphomaDong Won Baek, Joon Ho Moon, Jae Hoon Lee, et al.
Pageof 28

Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
Annals of Hematology|October 12, 2012
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangementHee-Jin Kim, Hee Kyung Ahn, Chul Won Jung, et al.
Transfusion|March 13, 2015
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overloadIl-Hwan Kim, Joon-Ho Moon, Sung-Nam Lim, et al.
Annals of Hematology|November 6, 2015
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplantJae-Sook Ahn, Jae-Young Kim, Hyeoung-Joon Kim, et al.
Leukemia|December 18, 2018
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemiaJong-Ho Park, Young Min Woo, Emilia Moonkyung Youm, et al.
Blood|August 16, 2018
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapseTaeHyung Kim, Joon Ho Moon, Jae-Sook Ahn, et al.
American Journal of Hematology|August 24, 2017
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapyHyungwoo Cho, Dok Hyun Yoon, Jung Bok Lee, et al.
Bone Marrow Transplantation|September 23, 2022
Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemiaGa-Young Song, TaeHyung Kim, Seo-Yeon Ahn, et al.
Acta Haematologica|December 7, 2011
Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemiaSoo Jung Lee, Byung Woog Kang, Joon Ho Moon, et al.
Annals of Hematology|September 13, 2013
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patientsKihyun Kim, Seok Jin Kim, Verena Voelter, et al.
Blood Research|August 13, 2025
A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphomaDong Won Baek, Joon Ho Moon, Jae Hoon Lee, et al.
Pageof 28